Why wait to prescribe TRELEGY for your patients with ongoing symptoms of COPD?

Meet

MARIA

a patient with COPD

Meet

MARIA

a patient with COPD

64-year-old treated with a TWICE-DAILY ICS/LABA

Lungs icon

At risk of exacerbation

64-year-old treated with a
TWICE-DAILY ICS/LABA

Lungs icon
Exacerbation icon

At risk of exacerbation

hero-border
3 dots

You may have patients who remain symptomatic with current COPD therapy

Gray lungs icon

88% OF PATIENTS WITH COPD

who had been prescribed FP/SAL, an ICS/LABA,
reported being symptomatic (CAT ≥10)1

Based on data from an observational claims-linked survey of Medicare Advantage enrollees ≥65 years of age who had been prescribed FP/SAL in the prior 6 months (n=397).1

Study Limitations: A claim for a prescription does not necessarily mean the medication was taken as prescribed. Diagnosis codes on medical claims do not conclusively demonstrate presence of disease. Findings may not be generalizable to uninsured or younger patient populations.1      

The GOLD Report supports escalation to triple therapy for patients with COPD who continue to experience persistent breathlessness or exacerbations on an ICS/LABA.2

 

3 dots

Your patients with COPD may be at risk for exacerbations if they:

Have had at least 1 exacerbation in the prior 12 months3

Are on maintenance therapy but have increased symptoms3

Experience worsening lung function3

Have required recent hospitalization due to an exacerbation4

Consequences of exacerbations can be significant

Caution icon
Associated with increased
risk of mortality5
Hospital icon

Most common reason for
COPD-related hospitalizations6

Economic burden icon

Major contributor to
economic burden2,7

Health-related quality of life icon
Decreased health-related
quality of life8

Just 1 moderate to severe exacerbation can lead to a significant decline in lung function.9

 

Does TRELEGY prevent exacerbations in patients with COPD?

Review data

 

Help your patients try TRELEGY.

Request samples now

 

Learn about a symptom assessment tool for your patients with COPD.

Find out more

See local coverage for TRELEGY vs other therapies.

Learn more